Vanguard Discloses 7.0% Stake in Celldex Therapeutics

TL;DR

**Vanguard now owns 7.0% of Celldex Therapeutics, holding 10.2M shares as of Dec 29, 2023.**

AI Summary

The Vanguard Group, a major investment firm, filed an updated SC 13G/A on February 13, 2024, disclosing its ownership in Celldex Therapeutics Inc. As of December 29, 2023, Vanguard beneficially owned 10,248,367 shares of Celldex Common Stock, representing 7.0% of the company's outstanding shares. This is an amendment to a previous filing, indicating a change in their holdings, which is important for investors to track as large institutional ownership can influence stock stability and perception.

Why It Matters

Large institutional ownership by firms like Vanguard can signal confidence in a company's long-term prospects and often provides a degree of stability to the stock price due to their buy-and-hold strategies.

Risk Assessment

Risk Level: low — This filing indicates a significant, but passive, institutional ownership, which generally reduces volatility rather than increasing risk.

Analyst Insight

An investor should note Vanguard's continued significant, but passive, stake in Celldex Therapeutics, which suggests institutional confidence and potential long-term stability, but does not indicate any immediate catalysts or changes in company strategy.

Key Numbers

• 10,248,367 — Shares Owned (Total number of Celldex Therapeutics Common Stock shares beneficially owned by The Vanguard Group.)
• 7.0% — Ownership Percentage (The percentage of Celldex Therapeutics' Common Stock owned by The Vanguard Group, indicating a significant institutional stake.)
• December 29, 2023 — Reporting Date (The specific date as of which Vanguard's ownership stake is being reported in this filing.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and institutional investor
• Celldex Therapeutics Inc (company) — subject company whose shares are being reported
• 10,248,367 (dollar_amount) — number of shares beneficially owned by Vanguard
• 7.0% (dollar_amount) — percentage of Celldex Therapeutics' class of securities owned by Vanguard
• December 29, 2023 (date) — date of the event which required the filing
• February 13, 2024 (date) — filing date of the SC 13G/A

Forward-Looking Statements

• Vanguard will maintain a significant, passive stake in Celldex Therapeutics for the foreseeable future. (The Vanguard Group) — high confidence, target: December 2024
• Celldex Therapeutics' stock price may experience increased stability due to Vanguard's substantial ownership. (Celldex Therapeutics Inc.) — medium confidence, target: June 2024

FAQ

Filing Documents

• tv0562-celldextherapeuticsin.htm (SC 13G/A) — 11KB
• 0001104659-24-020559.txt ( ) — 13KB

(a) - Name of Issuer

Item 1(a) - Name of Issuer: Celldex Therapeutics Inc

(b) - Address of Issuer's Principal Executive Offices

Item 1(b) - Address of Issuer's Principal Executive Offices: Perryville III Building, 53 Frontage Road, Suite 220 Hampton, NJ 08827

(a) - Name of Person Filing

Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930

(b) – Address of Principal Business Office or, if none, residence

Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355

(c) – Citizenship

Item 2(c) – Citizenship: Pennsylvania

(d) - Title of Class of Securities

Item 2(d) - Title of Class of Securities: Common Stock

(e) - CUSIP Number

Item 2(e) - CUSIP Number 15117B202

- Type of Filing

Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).

- Ownership

Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.

- Ownership of Five Percent or Less of a Class

Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

- Ownership of More Than Five Percent on Behalf of Another Person

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable

- Identification and Classification of Members of Group

Item 8 - Identification and Classification of Members of Group: Not applicable

- Notice of Dissolution of Group

Item 9 - Notice of Dissolution of Group: Not applicable

- Certification

Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

View Full Filing

View this SC 13G/A filing on SEC EDGAR